Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus PROMETRIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELALUTIN versus PROMETRIUM.
DELALUTIN vs PROMETRIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Progesterone binds to progesterone receptors in target tissues, promoting endometrial maturation, reducing uterine contractility, and suppressing ovulation.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
Oral: 200 mg once daily at bedtime for 12 consecutive days per 28-day cycle in combination with conjugated estrogens 0.625 mg daily. For secondary amenorrhea: 400 mg once daily at bedtime for 10 days. Intravaginal: 4% gel (90 mg) or 8% gel (180 mg) applied every other day for 6 doses in postmenopausal women with intact uterus on estrogen therapy.
None Documented
None Documented
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Terminal half-life: Approximately 16-18 hours for oral micronized progesterone (Prometrium); permits twice-daily dosing for luteal phase support.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Urine (50-60% as metabolites, <1% unchanged); feces (20-30% as metabolites); minor biliary elimination.
Category C
Category C
Progestin
Progestin